“Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s291, https://doi.org/10.25251/skin.7.supp.291.